

GLP-1 Agonist and SGLT-2 Inhibitor Monotherapy Trial Results

Drug	Class	HbA1c Reduction	Fasting BG Reduction	Weight change	CV Outcomes	FDA Approval
Semaglutide	GLP-1A	0.5 mg: 1.5% 1.0 mg: 1.8%	0.5 mg: - 29 mg/dL 1.0 mg: - 43 mg/dL	0.5 mg: - 10.1 lbs 1.0 mg: - 14.3 lbs	Decreased risk of CV events by 26%	Submitted; Awaiting FDA Approval
Bydureon (exenatide ER)	GLP-1A	2 mg: 1.6%	2 mg: 25 mg/dL	2 mg: - 5 lbs	No statistically significant change	Jan 2012
Victoza (liraglutide)	GLP-1A	1.2 mg: 0.8% 1.8 mg: 1.1%	1.2 mg: 15 mg/dL 1.8 mg: 26 mg/dL	1.2 mg: - 4.6 lbs 1.8 mg: - 5.5 lbs	FDA approved to reduce risk of MI, CVA & death	Jan 2010
Trulicity (dulaglutide)	GLP-1A	.75 mg: 0.8% 1.5 mg: 1.1%	.75 mg: 16 mg/dL 1.5 mg: 27 mg/dL	.75mg: - 2.9 lbs 1.5mg: - 4.1 lbs	Does not increase the chances of a CV event	Sept 2014
Farxiga (dapagliflozin)	SGLT2-I	5 mg: 1.2% 10 mg: 1.5%	5 mcg: 42 mg/dL 10 mcg: 46 mg/dL	5 mcg: - 5.7 lbs 10 mcg: - 6.0 lbs	Does not increase the chances of a CV event	Jan 2014
Invokana (canagliflozin)	SGLT2-I	100 mg: 0.8% 300 mg: 1.0%	100 mg: 27 mg/dL 300 mg: 35 mg/dL	100 mg: - 5.3 lbs 300 mg: - 7.5 lbs	Significantly reduces risk stroke, heart attack and CV death	Mar 2013
Jardiance (empagliflozin)	SGLT2-I	10 mg: 0.7% 25 mg: 0.8%	10 mg: 19 mg/dL 25 mg: 25 mg/dL	10 mg: - 4.9 lbs 25 mg: - 5.5 lbs	FDA approved to reduce risk of CV death	Aug 2014